% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Breitkreutz:125556,
      author       = {I. Breitkreutz and N. Becker$^*$ and A. Benner$^*$ and F.
                      Kosely and C. Heining and J. Hillengass$^*$ and G. Egerer
                      and A. D. Ho and H. Goldschmidt and M.-S. Raab$^*$},
      title        = {{D}ose-intensified bendamustine followed by autologous
                      peripheral blood stem cell support in relapsed and
                      refractory multiple myeloma with impaired bone marrow
                      function.},
      journal      = {Hematological oncology},
      volume       = {34},
      number       = {4},
      issn         = {0278-0232},
      address      = {New York, NY [u.a.]},
      publisher    = {Wiley Interscience},
      reportid     = {DKFZ-2017-01682},
      pages        = {200 - 207},
      year         = {2016},
      abstract     = {Therapeutic options in heavily pretreated
                      relapsed/refractory multiple myeloma patients are often very
                      limited because of impaired bone marrow function.
                      Bendamustine is effective in multiple myeloma and has a
                      favourable toxicity profile. We hypothesized that
                      dose-intensified bendamustine (180 mg/m(2) , day 1 and 2)
                      followed by autologous blood stem cell support (ASCS) would
                      improve bone marrow function with low post-transplant
                      toxicity in patients with severely impaired haematopoiesis.
                      We analyzed 28 consecutive myeloma patients, with a median
                      of three prior lines of therapy (range 2-7), who had
                      relapsed from the last treatment with very limited bone
                      marrow function and were therefore ineligible for
                      conventional chemotherapy, novel agents or trial enrolment.
                      Dose-intensified bendamustine with ASCS improved
                      haematopoiesis as reflected by increased platelet counts
                      (median 40/nl vs 94/nl, p = 0.0004) and white blood cell
                      counts (3.0/nl vs 4.8/nl, p = 0.02) at day +100. The
                      median time until engraftment of platelets (>50/nl) was
                      11 days (0-24 days) and of white cell counts (>1.0/nl)
                      0 days (0-24 days). At least, a minimal response was
                      achieved in $36\%$ of patients. The disease stabilization
                      rate was $50\%$ while the median progression-free survival
                      rate was limited to 2.14 months. Most importantly,
                      patients were once again eligible for alternative treatments
                      including enrolment into clinical trials. We conclude that
                      dose-intensified bendamustine followed by ASCS is safe and
                      feasible for multiple myeloma patients with very limited
                      bone marrow reserve. Copyright © 2015 John Wiley $\&$ Sons,
                      Ltd.},
      keywords     = {Bendamustine Hydrochloride (NLM Chemicals)},
      cin          = {G330 / G170 / C060 / E010},
      ddc          = {610},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)G170-20160331 /
                      I:(DE-He78)C060-20160331 / I:(DE-He78)E010-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25784529},
      doi          = {10.1002/hon.2199},
      url          = {https://inrepo02.dkfz.de/record/125556},
}